Combination of chemotherapy and recombinant interferon-alpha in advanced non-small cell lung cancer

Hastürk, Serap; Kurt, Bahar; Kocabaş, Ali; Nadirler, Fatih; Oruç, Oya Akpınar

doi:10.1016/s0304-3835(96)04541-7

Cited by 4 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of combined 13-cis-retinoic acid and IFN-· with or without irradiation against squamous cell carcinoma was investigated in another report: the overall response of all 16 evaluable cervical cancer patients was 5 out of 16 [111]. In a study on the effect of the addition of treatment with IFN-· to cisplatin-etoposide chemotherapy in patients with advanced non-small cell lung cancer, it was reported that the addition of IFN-· did not increase the therapeutic effectiveness of chemotherapy alone [112].…”

Section: Immunotherapy With Cell-free Productsmentioning

confidence: 99%

One Hundred Years of Cancer Immunotherapy: A Critical Appraisal

Ben-Efraim

1999

Tumor Biology

View full text Add to dashboard Cite

First attempts of cancer immunotherapy were made approximately 100 years ago on the assumption that tumor cells are recognized as ‘foreign’ by the immune system. Later on, a whole series of experimental animal tumor models were developed. They included the use of syngeneic tumors, spontaneously arising tumors and human tumor xenografts in immunodeficient mice. The experimental data contributed to our understanding of the interaction between immunocompetent cells and their products on the one hand and tumor cells on the other. On this basis, various immunotherapeutic protocols have been devised which included the use of ‘nonspecific’ components such as bacterial adjuvants, cytokines, NK cells and macrophages and attempts were made to raise specific T and B cell responses against tumor cells. Many human tumor-associated antigens have been characterized, and various ways of increasing the immunogenicity of human tumor cells have been described. Moreover, more insight has been achieved in defining ‘high risk’ populations on the basis of genetic background, the role of environmental factors and the characterization of ‘precancerous’ cells. Some cancer vaccines have been used in clinical trials which have resulted in partially beneficial therapeutic effects but have not provided a full solution for a rational use of immunotherapy against human neoplasia.

show abstract

Section: Immunotherapy With Cell-free Productsmentioning

confidence: 99%